IL2 and COVID-19: One of the first studies to emerge from Wuhan, China, described patients with severe COVID-19 complications, admitted into the intensive care unit (ICU), as being more likely to present with higher plasma levels of inflammatory markers, including the interleukin 2, 7, and 10 (IL2,IL7, IL10), GMCSF, IP10, MCP1, MIP1A, and tumour necrosis factor alpha (TNFα) [14].